Subscribe To Our Free Newsletter |
Zydus Lifesciences completes enrolment for clinical trial of Usnoflast
The company informed that ALS is a rare, progressive, and fatal neurodegenerative disease with an average life expectancy of 3 to 5 years from symptom onset